<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00196664</url>
  </required_header>
  <id_info>
    <org_study_id>2004-004102-24</org_study_id>
    <secondary_id>ANRS HC18 PAROPEG</secondary_id>
    <nct_id>NCT00196664</nct_id>
  </id_info>
  <brief_title>Efficacy of Paroxetine in the Prevention of Depressive Syndrome in Patients With Chronic Hepatitis C Treated by PEG-Interferon Alfa Plus Ribavirin</brief_title>
  <official_title>Assessment of the Efficacy of Paroxetine in the Prevention of Depressive Syndrome in Patients With Chronic Hepatitis C Treated by PEG-Interferon Alfa Plus Ribavirin. Multicentric, Double-Blinded, Randomized Study. ANRS HC18 Paropeg</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>French National Agency for Research on AIDS and Viral Hepatitis</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>French National Agency for Research on AIDS and Viral Hepatitis</source>
  <brief_summary>
    <textblock>
      Depression is a common side effect of interferon in the treatment of chronic hepatitis C. The
      aim of this study is to assess the efficacy and safety of paroxetine, an antidepressant
      agent, in the prevention of depression induced by PEG-interferon given for the treatment of
      chronic hepatitis C.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The aim of this study is to assess the efficacy and safety of paroxetine, an antidepressant
      agent, in the prevention of depression induced by PEG-interferon given for the treatment of
      chronic hepatitis C. This is a comparative study including two groups of patients randomly
      allocated : one with paroxetine and the other with the placebo. The rate of depression will
      be compared between the 2 groups
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2005</start_date>
  <completion_date type="Actual">February 2009</completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of depression based on MINI International Neuropsychiatric Interview (MINI, DSM IV)from D0 to W74</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evolution of depression score (MADRS and BDI scales) to W74,Quality of life (HQL questionnaire), Fatigue, Compliance to PEG-interferon and ribavirin, Virological response at W74 ,Safety</measure>
  </secondary_outcome>
  <enrollment type="Anticipated">144</enrollment>
  <condition>Chronic Hepatitis C</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paroxetine</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        - Chronic hepatitis C which should be treated by PEG-interferon alfa and ribavirin with no
        contra-indication to anti-viral treatment

        Exclusion Criteria:

          -  Allergy to paroxetine

          -  Current antidepressant treatment

          -  Depression diagnosed by the MINI International Neuropsychiatric Interview (MINI, DSM
             IV)

          -  History of bipolar syndrome

          -  History of psychotic syndrome

          -  Treatment by triptan, carbamazepine, millepertuis, methadone, oral anticoagulation

          -  Renal insufficiency

          -  HIV infection

          -  Breath feeding

          -  Contra-indication to PEG-interferon and or ribavirin
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jean Pierre Bronowicki, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Service d'Hépato-gastroenterologie, CHU de Nancy, Vandoeuvre France</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Faiez Zannad, MD</last_name>
    <role>Study Chair</role>
    <affiliation>C.I.C Nancy France</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Service d'Hépato-gastroentérologie CHU de Nancy</name>
      <address>
        <city>Vandoeuvre</city>
        <zip>54500</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>May 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 13, 2005</study_first_submitted>
  <study_first_submitted_qc>September 16, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 20, 2005</study_first_posted>
  <last_update_submitted>May 12, 2009</last_update_submitted>
  <last_update_submitted_qc>May 12, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 13, 2009</last_update_posted>
  <keyword>Chronic Hepatitis C</keyword>
  <keyword>Paroxetine</keyword>
  <keyword>Depression</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Hepatitis, Chronic</mesh_term>
    <mesh_term>Hepatitis C, Chronic</mesh_term>
    <mesh_term>Depressive Disorder</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Interferons</mesh_term>
    <mesh_term>Ribavirin</mesh_term>
    <mesh_term>Interferon-alpha</mesh_term>
    <mesh_term>Paroxetine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

